|
|
|
Insider
Information: |
Baker Brothers Life Sciences Lp |
Relationship: |
Director |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
15 |
|
Direct
Shares |
28,278,373 |
|
Indirect Shares
|
99,473,529 |
|
|
Direct
Value |
$945,830,915 |
|
|
Indirect Value
|
$2,912,474,466 |
|
|
Total
Shares |
127,751,902 |
|
|
Total
Value |
$3,858,305,381 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
13
|
1
|
Stock
price went up :
|
11
|
0
|
Stock
price went down : |
2
|
1
|
|
|
|
Gain/Loss Ratio : |
5.5
|
-1.0
|
Percentage
Gain/Loss : |
19.7%
|
-23.5%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Synageva BioPharma Corp |
GEVA |
Director |
2012-07-13 |
5,077,676 |
|
0 |
Premium* |
|
XOMA Corporation |
XOMA |
Director |
2012-07-19 |
13,606,093 |
|
0 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director |
2012-07-26 |
9,086,690 |
|
0 |
Premium* |
|
Acadia Pharmaceuticals Inc |
ACAD |
Director, 10% Owner |
2023-06-01 |
205,752 |
2023-06-01 |
39,330,977 |
Premium* |
|
Seagen Inc |
SGEN |
Former 10% Owner, Dire... |
2023-12-14 |
0 |
2023-12-14 |
0 |
Premium* |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2017-09-08 |
119,681 |
2017-09-08 |
822,826 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2014-03-10 |
1,613,076 |
Premium* |
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2017-06-15 |
131,963 |
2017-06-15 |
1,074,556 |
Premium* |
|
Beigene Ltd |
BGNE |
Director, 10% Owner |
2023-11-14 |
20,838 |
2023-11-14 |
9,878,124 |
Premium* |
|
Talis Biomedical Corp |
TLIS |
Director, 10% Owner |
2021-11-18 |
0 |
2021-11-18 |
7,625,425 |
Premium* |
|
Tscan Therapeutics, Inc. |
TCRX |
Director, 10% Owner |
2022-05-10 |
0 |
2022-05-11 |
2,528,583 |
Premium* |
|
DBV Technologies SA |
DBVT |
Director, 10% Owner |
2022-06-13 |
0 |
2022-06-13 |
29,190,248 |
Premium* |
|
Kiniksa Pharmaceuticals, Ltd. |
KNSA |
Director |
2023-06-06 |
29,680 |
2023-06-06 |
2,719,343 |
Premium* |
|
Igm Biosciences, Inc. |
IGMS |
Director |
2023-06-30 |
0 |
2023-09-29 |
2,896,968 |
Premium* |
|
Madrigal Pharmaceuticals Inc |
MDGL |
Director |
2023-11-14 |
0 |
2023-12-14 |
1,793,403 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SGEN |
Seagen Inc |
Former 10% Owner |
|
2023-12-14 |
4 |
D |
$229.00 |
$10,661,553 |
D/D |
(46,557) |
0 |
0 |
- |
|
SGEN |
Seagen Inc |
Former 10% Owner |
|
2023-12-14 |
4 |
D |
$229.00 |
$2,147,483,647 |
I/I |
(44,708,503) |
0 |
0 |
- |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-12-14 |
4 |
B |
$226.97 |
$4,710,893 |
I/I |
20,633 |
1,793,403 |
2.1 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-12-13 |
4 |
B |
$216.70 |
$17,805,684 |
I/I |
81,159 |
1,774,294 |
2.1 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-12-12 |
4 |
B |
$205.32 |
$7,548,616 |
I/I |
34,578 |
1,699,129 |
2.1 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-11-21 |
4 |
B |
$183.16 |
$12,128,340 |
I/I |
64,350 |
1,667,104 |
2.1 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-11-20 |
4 |
B |
$181.93 |
$3,846,575 |
I/I |
20,709 |
1,607,668 |
2.1 |
% |
|
BGNE |
Beigene Ltd |
Director |
|
2023-11-14 |
4 |
S |
$180.50 |
$198,550,000 |
I/I |
(1,100,000) |
9,691,294 |
0 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-11-17 |
4 |
B |
$167.63 |
$8,100,704 |
I/I |
46,370 |
1,588,541 |
2.1 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-11-15 |
4 |
B |
$161.97 |
$2,461,721 |
I/I |
15,199 |
1,545,775 |
2.1 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-11-14 |
4 |
B |
$156.42 |
$5,347,837 |
I/I |
34,188 |
1,531,757 |
2.1 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-11-14 |
4 |
B |
$152.21 |
$5,799,653 |
I/I |
37,660 |
1,500,227 |
2.1 |
% |
|
MDGL |
Madrigal Pharmaceuticals ... |
Director |
|
2023-11-13 |
4 |
B |
$136.18 |
$10,001,368 |
I/I |
69,839 |
1,465,494 |
2.1 |
% |
|
INCY |
Incyte Corp |
Director |
|
2017-03-31 |
4 |
A |
$133.67 |
$56,943 |
I/I |
426 |
767,237 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2017-09-08 |
4 |
B |
$132.00 |
$13,200,000 |
I/I |
100,000 |
789,416 |
2.25 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Director |
|
2017-06-14 |
4 |
B |
$118.00 |
$518,256 |
I/I |
4,392 |
7,321,850 |
2.1 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Director |
|
2017-06-15 |
4 |
B |
$116.54 |
$77,012,491 |
I/I |
656,387 |
980,146 |
2.1 |
- |
|
ALXN |
Alexion Pharmaceuticals I... |
Director |
|
2017-06-14 |
4 |
B |
$114.33 |
$156,915,444 |
I/I |
1,348,955 |
7,317,906 |
2.1 |
- |
|
INCY |
Incyte Corp |
Director |
|
2016-12-30 |
4 |
A |
$100.27 |
$56,853 |
I/I |
567 |
533,909 |
0 |
- |
|
BGNE |
Beigene Ltd |
Director |
|
2017-08-11 |
4 |
B |
$71.00 |
$12,499,976 |
I/I |
176,056 |
3,476,256 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2017-05-19 |
4 |
A |
$66.60 |
$492,840 |
I/I |
7,400 |
40,898,792 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2016-11-08 |
4 |
B |
$59.46 |
$19,403,299 |
I/I |
326,300 |
40,885,092 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2016-11-07 |
4 |
B |
$58.74 |
$3,301,345 |
I/I |
56,200 |
40,590,914 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2016-11-03 |
4 |
B |
$56.55 |
$21,586,884 |
I/I |
379,336 |
40,361,400 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2016-11-03 |
4 |
B |
$55.99 |
$11,196,763 |
I/I |
198,433 |
40,540,247 |
2.25 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|